CSF3 and neutropenia: Bone marrow suppression, represented by neutropenia (21.9%), was the most frequent grade 3 or 4 treatment-related adverse event, but neutrophil counts usually returned to normal after recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment.